IDEXX Laboratories to Release 2006 Fourth Quarter and Full-Year Financial Results

Westbrook, Maine, January 18, 2007—IDEXX Laboratories, Inc. (NASDAQ:IDXX), has scheduled the release of its 2006 fourth quarter and full-year financial results for Friday, January 26, at approximately 7:00 a.m. (eastern). The Company will conduct an analyst conference call beginning at 9:00 a.m. (eastern) on that day.

Individuals can access a live Webcast of the conference call through a link on the home page of the IDEXX Web site, www.idexx.com. An archived edition of the call will be available after 1:00 p.m. (eastern) via the same link.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 800-475-3716 or 719-457-2727 and reference confirmation code 1704816. Replay of the conference call will be available as of 12:00 p.m. (eastern) on January 26, through Friday, February 2, by dialing 719-457-0820 and referencing replay code 1704816.

IDEXX Laboratories to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

The Company also announced today that it will participate in the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference. Jonathan W. Ayers, Chairman, President and CEO, is scheduled to make a presentation on the Company on Tuesday, February 6, 2007 at 8:00 a.m. (eastern) at the Grand Hyatt in New York City. Individuals can access the live Webcast of the presentation through a link on the home page of the IDEXX Web site, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems, and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,500 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 (1.5 MB), and on the Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 (520 KB), in the section captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations."

This symbol indicates PDF-formatted materials. To view, you may need to download a free copy of Adobe^® Reader^® software.